Who is sponsoring NCT04038957?

NCT04038957 is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc..

What condition does NCT04038957 study?

NCT04038957 studies Schizophrenia.

What is the status of NCT04038957?

NCT04038957 is currently COMPLETED.

Last reviewed 2024-12-27 · How we verify

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

NCT04038957 PHASE1 COMPLETED Results posted

A clinical study to investigate the effect of an investigational drug as an added medication to an antipsychotic, in adults with schizophrenia, as measured positron emission tomography (PET) imaging . This study is accepting male and female participants between 18 years old -45 years old who have been diagnosed with schizophrenia. This study will be conducted in 2 locations in the UK. The study will last approximately 14 months.

Details

Lead sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase	PHASE1
Status	COMPLETED
Enrolment	22
Start date	Wed Aug 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Schizophrenia

Interventions

SEP-363856

Countries

United Kingdom